By admin 
The leadership carousel in the biotechnology sector continues to spin at a rapid clip, and this week, the spotlight falls on Rigel Pharmaceuticals, a South San Francisco-based firm that has spent the last two decades navigating the volatile waters of hematology and oncology. Rigel has officially announced the appointment of Alison Hannah, M.D., as its new Executive Vice President and Chief Medical Officer, a move that signals a strategic reinforcement of the company’s clinical development capabilities as it seeks to expand its footprint in the increasingly competitive rare disease and targeted oncology markets. Dr. Hannah, a seasoned veteran of the pharmaceutical industry with over three decades of experience, steps into the role previously occupied by a series of interim leaders and predecessors, bringing with her a reputation for navigating complex regulatory pathways and a deep understanding of the drug development lifecycle from early-phase trials to commercialization.
Dr. Hannah makes the move to Rigel from CytomX Therapeutics, where she served in a similar capacity as Chief Medical Officer. During her tenure at CytomX, she was instrumental in advancing the company’s "Probody" platform—a sophisticated technology designed to create conditionally activated biologics that remain inactive in healthy tissue but are triggered by proteases within the tumor microenvironment. This experience in precision medicine and site-specific activation is particularly relevant to Rigel’s current trajectory, as the company increasingly focuses on small molecules and therapies that require high degrees of selectivity to minimize systemic toxicity while maximizing therapeutic index.
Rigel’s decision to bring Hannah on board comes at a pivotal moment for the company. Rigel is perhaps best known for its flagship product, Tavalisse (fostamatinib disodium hexahydrate), the first and only spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. While Tavalisse has provided a steady revenue stream and established Rigel’s presence in the hematology space, the company has faced challenges in expanding the drug’s indications, most notably hitting a significant roadblock in its efforts to treat warm autoimmune hemolytic anemia (wAIHA). In that trial, the drug failed to meet its primary endpoint, a setback that forced the company to recalibrate its clinical strategy and lean more heavily into its oncology pipeline.
Beyond Tavalisse, Rigel has been aggressive in its pursuit of targeted oncology assets. A cornerstone of this effort is Rezlidhia (olutasidenib), an oral, potent, selective, small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). Rezlidhia was approved by the FDA in late 2022 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. The integration of olutasidenib into Rigel’s portfolio—following a licensing agreement with Forma Therapeutics—represented a shift toward a more diversified commercial-stage company. Dr. Hannah’s primary mandate will be to oversee the continued clinical development of olutasidenib, including exploring potential combination therapies and earlier-line settings, as well as managing the rest of Rigel’s early-to-mid-stage pipeline.
The "Coming and Going" of executives like Dr. Hannah is more than just a change in the organizational chart; it is a reflection of the broader talent war currently raging in the biotech hubs of the San Francisco Bay Area and Cambridge, Massachusetts. As the industry faces a bifurcated market—where high-interest rates and cautious venture capital spending contrast with a surge in breakthroughs in AI-driven drug discovery and antibody-drug conjugates (ADCs)—the value of an "operational" CMO cannot be overstated. Companies are no longer looking for mere scientific figureheads; they require medical chiefs who understand the "blocking and tackling" of clinical trial operations, the nuances of FDA advisory committee meetings, and the economic realities of drug pricing and reimbursement.
Dr. Hannah’s resume reads like a history of modern oncology. Before her stint at CytomX, she spent years as a consultant for nearly 30 different biotech companies, providing the kind of high-level strategic oversight that is often the difference between a successful IPO and a quiet dissolution. Her career also includes significant roles at Sugen, a pioneer in the development of kinase inhibitors. At Sugen, she was a key player in the development of Sutent (sunitinib), a multi-kinase inhibitor that eventually became a blockbuster for Pfizer in the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Her experience at Bristol-Myers Squibb (BMS) further solidified her pedigree, where she worked on the development of early immunotherapies long before "checkpoint inhibitor" became a household term in the medical community.
The hire is also a win for Rigel’s CEO, Raul Rodriguez, who has been vocal about the company’s need to transition from a research-heavy organization to a fully integrated commercial entity. Rodriguez has navigated Rigel through multiple cycles of boom and bust, and the addition of Hannah is seen by analysts as a stabilizing force. "Rigel is at a stage where they have the products, but they need to execute flawlessly on the data generation side to convince payers and physicians of the long-term value proposition," noted one industry analyst following the announcement. "Hannah has seen what ‘good’ looks like at the highest levels of Big Pharma, and bringing that rigor to a mid-cap player like Rigel is a logical next step."
However, the role of a Chief Medical Officer in today’s environment is fraught with difficulty. The FDA’s increasingly stringent requirements for post-marketing surveillance and the implementation of the Inflation Reduction Act (IRA) have changed the math for drug development. CMOs must now weigh the clinical potential of a drug against the "negotiated" price it might fetch years down the line, often making difficult decisions to kill promising programs early if the market access path looks too narrow. For Rigel, which operates in the orphan disease space, these pressures are amplified. The company must ensure that its clinical trials are not only scientifically sound but also designed to produce the specific health-economic data that insurers demand before granting favorable formulary placement.
In the Pharmalot tradition, it is also worth noting the human element of these transitions. As the original snippet alluded to, "all work and no play can make for a dull chief medical officer." The culture of biotech leadership is often criticized for its burnout rates and the "revolving door" phenomenon where executives jump from one startup to another every 18 months. Dr. Hannah’s long-term engagements at her previous posts suggest a level of commitment that Rigel shareholders will likely find reassuring. Her transition also highlights a growing trend of female leadership in the C-suite of biotech, a sector that has historically struggled with gender diversity at the highest levels of management.
As Rigel looks toward the future, the integration of Dr. Hannah into the executive team will be a key metric for investors to watch. The company’s pipeline includes several interesting, if early, assets, such as their R552 program—a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor. This program, which is being developed in collaboration with Eli Lilly, represents a foray into the massive but treacherous market for chronic inflammatory diseases like psoriasis and rheumatoid arthritis. Managing a partnership with a giant like Lilly requires a specific kind of diplomatic and scientific finesse, another area where Hannah’s deep industry ties will likely be put to use.
The biotech industry remains a high-stakes game of musical chairs, but for Rigel Pharmaceuticals, the music has stopped on a candidate with a proven track record. Whether Dr. Hannah can help Rigel transcend its status as a niche hematology player and become a broader oncology powerhouse remains to be seen, but her appointment is a clear signal of intent. In an era where the cost of drug development continues to soar and the margin for error continues to shrink, Rigel is betting that experience is the ultimate hedge against uncertainty.
The "Coming and Going" column will continue to track these shifts, as each hire and departure provides a breadcrumb trail toward the next major shift in the pharmaceutical landscape. For now, the industry watches Rigel, waiting to see if this new medical leadership can turn clinical potential into commercial reality. The road ahead for Rigel involves not just the management of current FDA-approved therapies, but the cultivation of a pipeline that can withstand the rigors of modern clinical scrutiny. With Dr. Hannah at the medical helm, the company has at least secured a navigator who has successfully charted these waters many times before.
